The decrease in metabolic activity we found after treatment with these agents complies with our data after esiRNA-mediated NAMPT inhibition, as well as reports of decreased levels of NAD+, NADH, NADP+ and NADPH in glioma cells with and without IDH1 mutation [19,41,42,43,44]. This evidence concerns the gene NAMPT and central nervous system cancer.